An Open-Label, Multi-Centre, Randomised, Parallel-Arm One-Year Trial, Comparing the Efficacy and Safety of Degarelix Three-Month Dosing Regimen With Goserelin Acetate in Patients With Prostate Cancer Requiring Androgen Deprivation Therapy.
Phase of Trial: Phase III
Latest Information Update: 29 Aug 2016
At a glance
- Drugs Degarelix (Primary) ; Goserelin
- Indications Prostate cancer
- Focus Biomarker; Therapeutic Use
- Sponsors Ferring Pharmaceuticals
- 10 Jun 2017 Biomarkers information updated
- 01 Feb 2014 Pooled analysis presented at the 2014 Genitourinary Cancers Symposium.
- 27 Sep 2012 New source identified and integrated (Extension study, German Clinical Trials Register: DRKS00004078).
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History